ESSA Pharma is a clinical stage pharmaceutical company. Co. is focused on developing therapies for the treatment of prostate cancer in patients whose disease is progressing despite treatment with care therapies, including anti-androgen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide. Co.'s series of investigational compounds, including its product candidate EPI-7386, is used in patients with castration-resistant prostate cancer through anti-hormone-based therapies. The compounds are designed to disrupt the androgen receptor (AR) signaling pathway and prevent AR activation through selective binding to the N-terminal domain of the AR. The EPIX average annual return since 2015 is shown above.
The Average Annual Return on the EPIX average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether EPIX average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EPIX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|